methylphenidate
methylphenidate is listed in the FDA National Drug Code directory with 16 NDC codes, marketed under brand names including Methylphenidate Transdermal System, Methylphenidate, Daytrana. Available dosage forms: patch, capsule, extended release.
Drug details
- Generic Name
- methylphenidate
- Brand Names
- Methylphenidate Transdermal System, Methylphenidate, Daytrana
- Application Number
- NDA021514
- Sponsor
- PADAGIS US LLC
- NDC Codes
- 16
- Dosage Forms
- PATCH, CAPSULE, EXTENDED RELEASE
- Routes
- TRANSDERMAL, ORAL
- Active Ingredients
- METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE Methylphenidate transdermal system is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Limitations of Us e The use of methylphenidate transdermal system is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.8) , Use in Specific Populations (8.4) ] . Methylphenidate transdermal system is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. ( 1 ) Limitations of Use The use of methylphenidate transdermal system is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.8 , 8.4 ).